Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

por Smolen, J S, Emery, P, Ferraccioli, G F, Samborski, W, Berenbaum, F, Davies, O R, Koetse, W, Purcaru, O, Bennett, B, Burkhardt, H
Publicado 2015